Oruka Therapeutics, Inc.
Every calculator, already run for ORKA
Open the full toolkit →You have the numbers on ORKA. Get the argument.
A written report on which of these readings actually decide the outcome for Oruka Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
13 analysts covering ORKAAnalyst Price Target Disagreement for Oruka Therapeutics, Inc.
Wall Street's bull case implies +118% from the current price; the bear case implies +28%. A 91% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for ORKA
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park…
ORKA — frequently asked
Is ORKA a buy right now?
Wall Street's consensus rating on Oruka Therapeutics, Inc. is Strong Buy across 13 analysts, with a mean price target of $155.00 (+69% vs. the current $91.65). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is ORKA's next earnings date?
Oruka Therapeutics, Inc. is next scheduled to report earnings around Nov 11, 2026. A full ORKA research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Oruka Therapeutics, Inc.?
Analysts covering Oruka Therapeutics, Inc. (ORKA) range from a bear-case target of $117.00 to a bull-case high of $200.00, with a mean consensus target of $155.00 across 12 analysts. The spread of $83.00 (91% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Oruka Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Oruka Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ORKA research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Oruka Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.